Survodutide

Survodutide Research Standard

Survodutide (CAS 2805997-46-8), also indexed as BI 456906, is a synthetic peptide dual agonist at the GLP-1 receptor and the glucagon receptor, supplied as a 10 mg lyophilized powder in a 3 mL vial. Like mazdutide it is a unimolecular dual agonist rather than a co-formulation, so its two activities travel on one molecule at a fixed designed ratio.^[1]

Mechanism of Action & Research Context

The molecular targets are the GLP-1 receptor (GLP-1R) and the glucagon receptor (GCGR), both class B GPCRs.

• Two receptors, two contributions. The GLP-1 receptor arm supplies the anorectic and insulinotropic activity; the glucagon receptor arm supplies an energy expenditure effect. Work on unimolecular multi-agonists identifies GcgR activation as the differentiating factor between incretin mono- or dual-agonists and agents that add glucagon — it is what the second receptor is for.^[1]

• The potency ratio is a design parameter. These are not simply two agonists bolted together. Relative receptor potency is empirically optimised, and shifting the ratio changes the pharmacology rather than merely the strength — which is why one dual agonist is not a substitute for another in an experiment.^[1]

• Glucagon engagement is not monotonic. The most useful result for anyone designing a dose-response with this class: in a diet-induced obese mouse model, a long-acting GLP-1R/GCGR dual agonist produced its maximal benefit on hepatic endpoints at a middle dose. The highest dose drove further liver fat reduction and a large induction of oxidative phosphorylation genes, but also exaggerated body weight loss and downregulation of a co-expressed gene module covering steroid hormone biology, bile secretion and retinol metabolism. The authors describe the liver-health benefit of glucagon-receptor engagement as a bell-shaped curve. A design that only tests low and high doses can miss the optimum entirely.^[2]

• Dual agonism outperformed the GLP-1 mono-agonist at matched weight loss. In the same model the dual agonist reduced hepatic steatosis more than semaglutide at equal body weight loss, measured by three independent methods — so the additional effect is attributable to the glucagon arm rather than to weight change alone.^[2]

Research Applications

Primary fields of in vitro and preclinical laboratory investigation include:

• Receptor potency and selectivity assays at GLP-1R and GCGR, including potency-ratio characterisation.^[1]

• Signalling and functional assays in cell lines expressing recombinant or endogenous incretin receptors.^[1]

• Preclinical metabolic models, including diet-induced obese rodents with hepatic histology and transcriptome endpoints.^[2]

• Dose-response design across a range wide enough to detect a non-monotonic optimum.^[2]

• Comparative profiling against GLP-1R mono-agonists at matched body weight.^[2]

Analytical Documentation

Purity and identity vary by manufacturing lot. Kimera Chems does not publish a single fixed purity figure for this item; refer to the batch-specific Certificate of Analysis (COA) issued for the lot received, which reflects third-party analytical testing for that lot.

References

1. Knerr PJ, Mowery SA, Douros JD, et al. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. Mol Metab. 2022;63:101533. doi:10.1016/j.molmet.2022.101533
2. Monfeuga T, Norlin J, Bugge A, et al. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients. Mol Metab. 2024;79:101850. doi:10.1016/j.molmet.2023.101850

Storage & Handling

Store at controlled room temperature, sealed and protected from light.

Storage guidance is a house recommendation. Analytical documentation is per-lot release testing.

Related Research Compounds

• Mazdutide
• SANA (MVD1)
• AOD-9604
• Fragment 176-191

Research Use Only Disclaimer: This product is labeled and sold "For Research Use Only - NOT FOR HUMAN CONSUMPTION." It is not a drug, dietary supplement, food, cosmetic, or medical device, and it is not approved by the FDA or any other regulator for human or veterinary use. It is supplied to approved account holders as a research chemical for laboratory use and must be handled in accordance with applicable law.